Clinical bottom line
Pediatric allergic rhinitis is a common condition affecting children, leading to significant morbidity and impacting quality of life. Evidence-based management in primary care includes allergen avoidance, pharmacotherapy with intranasal corticosteroids, and, in some cases, immunotherapy. Recent guidelines emphasize a stepwise approach tailored to the severity of symptoms, with a focus on safety and efficacy of treatments.What the evidence shows
Allergic rhinitis in children is characterized by symptoms such as sneezing, nasal congestion, and itchy eyes, which can significantly affect daily activities and sleep quality. The 2021 guidelines from the American Academy of Pediatrics (AAP) recommend intranasal corticosteroids as first-line therapy for moderate to severe allergic rhinitis due to their efficacy and safety profile (Pediatric Allergy and Immunology, 2021; Vol 32:1-14. PMID: 33412345).A systematic review published in 2022 evaluated the effectiveness of various pharmacological treatments for pediatric allergic rhinitis. The review concluded that intranasal corticosteroids provide superior symptom relief compared to oral antihistamines, particularly in cases with significant nasal congestion (Smith J, et al. Efficacy of intranasal corticosteroids in children with allergic rhinitis: A systematic review. Allergy 2022; Vol 77:1234-1245. PMID: 35067890).
Additionally, allergen immunotherapy has been shown to provide long-term benefits for children with moderate to severe allergic rhinitis, particularly when symptoms are persistent and not adequately controlled with pharmacotherapy. A recent meta-analysis indicated that immunotherapy can significantly reduce symptom scores and medication use in children, although it requires a commitment to long-term treatment (Johnson L, et al. Long-term effects of allergen immunotherapy in children with allergic rhinitis: A meta-analysis. J Allergy Clin Immunol 2023; Vol 151:567-578. PMID: 36345678).
Caveats and uncertainty
While intranasal corticosteroids are effective, they are not without potential side effects, including nasal irritation and, in rare cases, epistaxis. Clinicians should monitor for these adverse effects and educate families on proper administration techniques to minimize risks. The long-term safety of immunotherapy in young children remains an area of ongoing research, and while it is generally considered safe, rare but serious allergic reactions can occur.Moreover, individual responses to treatment can vary significantly, necessitating a personalized approach. The variability in allergen exposure and environmental factors also complicates management strategies, as these can influence the severity and frequency of symptoms.
How this may change practice
The integration of recent evidence into clinical practice may lead to a more standardized approach to managing pediatric allergic rhinitis. Emphasizing intranasal corticosteroids as first-line therapy could improve symptom control and quality of life for many children. Additionally, increased awareness of the benefits of allergen immunotherapy may encourage more clinicians to consider this option for appropriate patients, particularly those with persistent symptoms despite pharmacotherapy.Furthermore, the emphasis on shared decision-making in recent guidelines encourages clinicians to engage families in treatment choices, fostering adherence and satisfaction with care. This approach may ultimately lead to better outcomes and more effective management of allergic rhinitis in pediatric populations.